SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JANUARY 11, 2000
PHARMACEUTICAL FORMULATIONS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-11274 22-2367644
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
460 PLAINFIELD AVENUE, EDISON, NEW JERSEY 08818
(Address of Principal Executive Offices, including Zip Code)
Registrant's telephone number, including area code: 732-985-7100
N.A.
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS
The Company made the December 15, 1999 interest payments due under its
8% Convertible Subordinated Debentures Due 2002 on January 11, 2000. Such
payments were within the 30 day period allowed before such nonpayment would
become an event of default under the debenture indenture.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMACEUTICAL FORMULATIONS, INC.
By: /S/ CLIFFORD H. STRAUB, JR.
-----------------------------
Name: Clifford H. Straub, Jr.
Title: Senior Vice President-Chief
Administrative Officer;
Chief Financial Officer
Dated: January 13, 2000
